Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis
Abstract
The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 2014, respectively. An estimated one third of patients with MDR-TB would benefit from the inclusion of these drugs in their treatment regimens.PubMed ID
29562988Language
enISSN
1815-7920ae974a485f413a2113503eed53cd6c53
10.5588/ijtld.17.0706